Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

June 22, 2017

At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report

News

Ninety-four percent of patients with chronic lymphocytic leukemia and 79 percent with mantle cell lymphoma responded to treatment with a combination of TGR-1202 (umbralisib), Imbruvica (ibrutinib), and TG-1101, according to updated Phase ... Read more

June 20, 2017June 20, 2017

Duvelisib Safe, Effective in Refractory Non-Hodgkin’s Lymphoma Patients, DYNAMO Study Shows

News

Treatment with Verastem’s duvelisib has shown sustained efficacy and safety in a trial with indolent non-Hodgkin’s lymphoma (iNHL) patients who had not responded well to Rituxan (rituximab) and chemotherapy or ... Read more

June 13, 2017June 13, 2017

Adcetris Shows Promise in Phase 3 Trial to Treat Certain Cutaneous T-Cell Lymphoma Patients

News

The investigational therapy Adcetris (brentuximab vedotin) shows promise as a potential treatment for patients with cutaneous T-cell lymphoma (CTCL), according to results of a Phase 3 clinical trial. Findings were published in ... Read more

May 2, 2017

Lymphoma Survivor Meets Woman Who Saved His Life with Stem Cell Donation

News

Almost two years after Peter Levine received a stem cell donation to treat his non-Hodgkin T-cell lymphoma from a stranger, the Boston native had a chance to thank the donor — 24-year-old ... Read more

February 14, 2017

New Oral Drug Shows Promise in Halting Growth of B-Cell Lymphoma Tumors

News

By simultaneously inhibiting two proteins that cancer cells need to survive, researchers offer a potentially promising therapeutic approach to treat B-cell lymphomas, according to a new study. CUDC-907, a new oral ... Read more

December 21, 2016

Opdivo May Help Those With Two Types of Non-Hodgkin’s Lymphoma

News

The FDA-approved Hodgkin’s-lymphoma treatment Opdivo (nivolumab) may also be effective against primary central nervous system lymphoma (PCNSL) or primary testicular lymphoma (PTL), case studies suggest. Researchers presented the results at ... Read more

December 15, 2016

Blood Transplants with Cell Mutations Raise Risk of Second Cancers in Lymphoma Patients

News

Lymphoma patients receiving transplant treatment with their own blood stem cells may be at risk of developing another blood cancer, according to a presentation at the 58th annual meeting of the ... Read more

December 1, 2016

Palliative Care Helps Blood Cancer Patients Undergoing Bone Marrow Transplants

News

Patients undergoing bone marrow transplants (HCT) to treat blood cancers such as lymphoma or leukemia may benefit from palliative care during their time in the hospital, according to a new ... Read more

November 21, 2016

Novartis to Present New Data on Potential Lymphoma Treatments

News

Novartis will present the most recent clinical data from its cancer research program at the upcoming 58th American Society of Hematology (ASH) Annual Meeting & Exposition Dec. 3-6 in San Diego and ... Read more

November 15, 2016

FDA Grants Breakthrough Therapy Designation to Adcetris for Certain Lymphoma Subtypes

News

The U.S. Food and Administration (FDA) has granted Breakthrough Therapy Designation to Seattle Genetics’ Adcetris (brentuximab vedotin) as a therapy for the most common subtypes of cutaneous T-cell lymphoma (CTCL), ... Read more